Senior Director
Pfizer Inc
San Diego, California
Weiwei Tan is Senior Director of Oncology Clinical Pharmacology group for Global Product Development at Pfizer. She received her Bachelor (Pharmacy) and Master (Pharmaceutics) degrees from School of Pharmaceutical Sciences at Peking University and Ph.D. in Pharmacokinetics from the University of Saskatchewan, Canada. Weiwei has 20+ years of drug development experience, obtained at pharma/biotech companies, encompassing drug discovery, development and post-approval research. Weiwei has led the clinical pharmacology efforts of international regulatory submissions (NDAs, sNDAs, and INDs) and corresponding rapid response activities, with close collaboration with DMPK, clinical, biostatistics, medical affairs, and regulatory affairs. She was the global clinical pharmacology lead for Xalkori® (crizotinib), the first-in-class ALK inhibitor for the treatment of ALK-positive non-small cell lung cancer, throughout the research and development of this drug from drug identification, First-in-Patient, until successful world-wide NDA submission and approval. Weiwei authored more than 50 manuscripts and abstracts in oncology and clinical pharmacology disciplines. Weiwei currently serves on the Regulatory Guidance Committee of Clinical Pharmacology Leadership Group for the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).
Disclosure information not submitted.
Wednesday, October 19, 2022
9:00 AM – 11:00 AM ET